Yervoy benefit investigated

In an interview on the ABC’s Four Corners last week, PBAC chair Dr Suzanne Hill said the government’s decision to seek such data for the first time was the result of the committee having to increasingly make decisions to list drugs “on the basis of smaller clinical trials”.

The drug’s listing is anticipated to save patients more than $110,000 a year.

The ABC reported that despite costing the government $430 million over the next four years, there had been no attempt to “systematically follow up with patients to see